Biopharma R&D productivity to slow without blockbuster drugs
According to a new report from EP Vantage, despite a surge in R&D productivity during the past couple of years, the situation might see a dramatic change this year. The rush of drugs that have hit the market and rapidly gone on to achieve blockbuster status has certainly driven investor confidence and share price valuations.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-877-857-2477
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter